Knight Therapeutics (GUD) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Share on StockTwits

Knight Therapeutics (TSE:GUD) released its quarterly earnings data on Thursday. The company reported C$0.04 EPS for the quarter, beating the consensus estimate of C$0.03 by C$0.01, Morningstar.com reports. The business had revenue of C$3.89 million for the quarter, compared to analysts’ expectations of C$2.55 million.

Knight Therapeutics stock opened at C$7.55 on Friday. Knight Therapeutics has a one year low of C$7.36 and a one year high of C$8.81. The firm has a market cap of $1.08 billion and a P/E ratio of 34.79.

Separately, Raymond James reaffirmed an “outperform” rating and set a C$10.25 price objective on shares of Knight Therapeutics in a research report on Wednesday, January 16th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of C$10.06.

TRADEMARK VIOLATION WARNING: “Knight Therapeutics (GUD) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS” was first reported by Fairfield Current and is the sole property of of Fairfield Current. If you are viewing this story on another site, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The legal version of this story can be viewed at https://www.fairfieldcurrent.com/news/2019/03/15/knight-therapeutics-gud-releases-quarterly-earnings-results-beats-expectations-by-0-01-eps.html.

About Knight Therapeutics

Knight Therapeutics Inc operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Impavido, an alkyllysophospholipid analogue drug for visceral and cutaneous Leishmaniasis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; and Flat Tummy Tea, a herbal detox tea.

Featured Article: Do investors pay a separate front-end load every time they buy additional shares?

Earnings History for Knight Therapeutics (TSE:GUD)

Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply